Zura Bio Limited Class A Ordinary Shares

ZURANASDAQ • USD
1.04 USD
↘ 0.05 (4.17%)AT CLOSE (03:59 PM EST)
1.03
↘ 0.00 (0.10%)
POST MARKET (AS OF 07:42 PM EST)
Post Market
AS OF 07:42 PM EST
1.03
↘ 0.00 (0.10%)
🟢Market: OPEN

Zura Bio Limited Class A Ordinary Shares (ZURA) trades at $1.03 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Nov 17, 2026.

Open?$1.05
High?$1.07
Low?$0.98
Prev. Close?$1.08
Volume?3.5M
Avg. Volume?7.0M
VWAP?$1.01
Rel. Volume?0.50x
Bid / Ask
Bid?$0.87 × 100
Ask?$1.20 × 100
Spread?$0.33
Midpoint?$1.03
Valuation & Ratios
Market Cap?104.0M
Shares Out?96.3M
Float?55.1M
Float %?57.5%
P/E Ratio?N/A
P/B Ratio?0.59
EPS?-$1.27
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Employees
40
Market Cap
104.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2023-03-21
Address
4225 EXECUTIVE SQUARE
LA JOLLA, CA 92037
Phone: 858-247-0520
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
9
Momentum?
77
Short Sent.?
48
Piotroski F-Score?0/9Weak
Altman Z-Score?0.86Distress
Confidence?45%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?15.38%High
Short Interest?8.5M
Days to Cover?1.8
Free Float55.1M
Avg Daily Volume4.7M
Settlement Date2026-10-30
Financial Health
Current Ratio?11.29Strong
Quick Ratio?11.29Strong
Cash Ratio?11.06Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.59CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
0.8CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-68.8%WEAK▾
ROA?
S&P
3
-62.8%WEAK▾
Cash Flow & Enterprise
FCF?$-22354395
Enterprise Value?$-83620556
Fundamentals ratios updated end of day